Formosa Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• APP13007, 0.05% · Ophthalmology
  APP13007 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.

Phase 2 pipeline

• APP13007, 0.1% · Diabetes
  APP13007 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Formosa Pharmaceuticals, Inc. portfolio CI brief
• Formosa Pharmaceuticals, Inc. pipeline updates RSS